any clues?, page-3

Analyst downgrade by RBS Australia as far I can tell:

CXS: RBS Australia rates CXS as Downgrade to Hold from Buy
Target $0.45 (was $1.51). The broker notes the Oncology Drug Advisory Committee has questioned the validity and reliability of the tests the company used in testing Omapro, which means no approval for Omapro is likely in the short-term. This sees the broker factor in some delays into its model and the cuts to its forecasts mean a reduction in price target. Until there is greater clarity with respect to the outlook the broker has downgraded to a Hold rating. Target price is $0.45 Current Price is $0.44 Difference: $0.01

If CXS meets the RBS Australia target it will return approximately 2% (excluding dividends, fees and charges). The company's fiscal year ends in June. RBS Australia forecasts a full year FY10 dividend of 0.00 cents and EPS of -3.90 cents.

http://www.hotcopper.com.au/post_single.asp?fid=287&tid=1135101&msgid=6354373

Seems that these analysts need to be locked up in a dark window-less room before giving their price estimates. Quite clearly they have looked at last close price, tagged on a cent and said that looks about right.